Stereotaxis Inc STXS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Stereotaxis to Present at Upcoming Investor Conferences
-
Stereotaxis Robotic Technology to be Featured during Heart Rhythm Society’s HRX Congress
-
Stereotaxis Gets Key EU Clearance to Market GenesisX Robotic System
-
Stereotaxis Reports 2024 Second Quarter Financial Results
-
Stereotaxis Achieves CE Mark in Europe and Submits 510(k) in the US for Next Generation Robotic System GenesisX
-
Stereotaxis to Report Second Quarter 2024 Financial Results on August 12, 2024
-
Stereotaxis Strengthens Board of Directors with Appointment of Nachum Shamir
Trading Information
- Previous Close Price
- $1.99
- Day Range
- $1.98–2.07
- 52-Week Range
- $1.40–3.29
- Bid/Ask
- $1.89 / $2.50
- Market Cap
- $168.47 Mil
- Volume/Avg
- 204,770 / 316,472
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 6.98
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service and accessories stream. The company generates the majority of revenue from the United States.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 122
- Website
- https://www.stereotaxis.com
Competitors
Valuation
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Price/Earnings (Normalized) | — | 76.71 |
Price/Book Value | 14.54 | 11.75 |
Price/Sales | 6.98 | 23.09 |
Price/Cash Flow | — | 60.38 |
Price/Earnings
STXS
ISRG
Financial Strength
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Quick Ratio | 1.43 | 4.03 |
Current Ratio | 2.29 | 5.15 |
Interest Coverage | — | — |
Quick Ratio
STXS
ISRG
Profitability
|
Metric
|
STXS
|
ISRG
|
|---|---|---|
Return on Assets (Normalized) | −24.53% | 14.89% |
Return on Equity (Normalized) | −62.60% | 17.17% |
Return on Invested Capital (Normalized) | −41.02% | 15.09% |
Return on Assets
STXS
ISRG
Medical Instruments & Supplies Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Intuitive Surgical Inc
ISRG
| Mzxxhtzrc | Hnj | $172.8 Bil | |||
| Becton Dickinson & Co
BDX
| Qzdzbjy | Fvsvww | $68.6 Bil | |||
| Alcon Inc
ALC
| Nqjylthlf | Nvqtpx | $48.6 Bil | |||
| ResMed Inc
RMD
| Qzhvglyvsm | Wljbhd | $35.6 Bil | |||
| Coloplast AS ADR
CLPBY
| Spjlszjtv | Mlmj | $29.1 Bil | |||
| West Pharmaceutical Services Inc
WST
| Yncvxhqfk | Xgd | $22.3 Bil | |||
| The Cooper Companies Inc
COO
| Ttvrtpxvc | Zwqxgq | $21.8 Bil | |||
| Baxter International Inc
BAX
| Mmchyycn | Cyrqcwy | $19.7 Bil | |||
| Align Technology Inc
ALGN
| Lbsdljtsf | Gmspzl | $18.6 Bil | |||
| Hologic Inc
HOLX
| Gthmchrj | Glfsbs | $18.6 Bil |
United States